Gilead Sciences Inc. (NASDAQ:GILD) – Leerink Swann decreased their Q3 2016 earnings per share estimates for shares of Gilead Sciences in a report released on Tuesday. Leerink Swann analyst G. Porges now expects that the brokerage will post earnings per share of $2.91 for the quarter, down from their previous estimate of $2.95. Leerink Swann has a “Market Perform” rating and a $94.00 price target on the stock. Leerink Swann also issued estimates for Gilead Sciences’ FY2016 earnings at $11.89 EPS, FY2017 earnings at $11.12 EPS, FY2018 earnings at $10.66 EPS, FY2019 earnings at $10.63 EPS and FY2020 earnings at $11.33 EPS.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.02 by $0.06. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The company had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. During the same quarter in the previous year, the firm posted $3.15 EPS. The firm’s quarterly revenue was down 5.7% on a year-over-year basis.
GILD has been the subject of a number of other reports. Jefferies Group decreased their price target on Gilead Sciences from $93.00 to $91.00 and set a “hold” rating for the company in a research note on Wednesday, August 31st. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Monday. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $108.00 price target on shares of Gilead Sciences in a research note on Wednesday, August 31st. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $93.97 price target for the company in a research note on Tuesday, July 26th. Finally, S&P Equity Research reiterated a “strong-buy” rating on shares of Gilead Sciences in a research note on Wednesday, July 27th. Eleven equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. Gilead Sciences currently has a consensus rating of “Buy” and an average target price of $104.34.
Gilead Sciences (NASDAQ:GILD) traded down 0.22% during trading on Thursday, reaching $78.80. The company’s stock had a trading volume of 2,941,236 shares. The stock has a market capitalization of $103.99 billion, a price-to-earnings ratio of 6.92 and a beta of 1.06. Gilead Sciences has a 52 week low of $76.67 and a 52 week high of $111.11. The firm has a 50 day moving average of $79.44 and a 200 day moving average of $85.67.
Several large investors have recently added to or reduced their stakes in the stock. Van Hulzen Asset Management LLC raised its stake in Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 100 shares during the last quarter. Joel Isaacson & Co. LLC raised its stake in Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 226 shares during the last quarter. Roble Belko & Company Inc raised its stake in Gilead Sciences by 340.5% in the second quarter. Roble Belko & Company Inc now owns 1,339 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 1,035 shares during the last quarter. Loomis Sayles & Co. L P raised its stake in Gilead Sciences by 23.3% in the first quarter. Loomis Sayles & Co. L P now owns 1,591 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 301 shares during the last quarter. Finally, Pinkerton Retirement Specialists LLC raised its stake in Gilead Sciences by 9,305.9% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,599 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 1,582 shares during the last quarter. 77.94% of the stock is owned by institutional investors and hedge funds.
In related news, EVP Paul Rutherford Carter sold 2,000 shares of Gilead Sciences stock in a transaction on Friday, July 1st. The shares were sold at an average price of $83.12, for a total value of $166,240.00. Following the completion of the sale, the executive vice president now owns 63,122 shares of the company’s stock, valued at approximately $5,246,700.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction on Thursday, September 22nd. The shares were sold at an average price of $81.84, for a total transaction of $409,200.00. Following the completion of the sale, the executive vice president now directly owns 132,964 shares of the company’s stock, valued at approximately $10,881,773.76. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Friday, September 16th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 2.38%. The ex-dividend date is Wednesday, September 14th. Gilead Sciences’s dividend payout ratio is currently 16.56%.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.